Search

Your search keyword '"Vose, Julie M."' showing total 1,904 results

Search Constraints

Start Over You searched for: Author "Vose, Julie M." Remove constraint Author: "Vose, Julie M."
1,904 results on '"Vose, Julie M."'

Search Results

151. Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

152. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

153. BET Inhibition As a Targeted Epigenetic Approach to Reverse T Cell Dysfunction in Chronic Lymphocytic Leukemia

154. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

155. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

157. Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

158. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

160. 2021 American Society of Hematology: Program Highlights

161. Looking Ahead: What's Next for Hematology/Oncology in 2022?

162. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort

163. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

165. Prognostic Factors for Advanced-Stage Human Immunodeficiency Virus-Associated Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Combined Antiretroviral Therapy: A Multi-Institutional Retrospective Study

166. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

167. Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma

169. Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

170. Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma

172. A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies

173. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma

176. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

177. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

178. Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

180. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma

181. Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

182. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

183. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

184. Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)

185. Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant

186. Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning

188. LEADing the Way: Leadership, Empowerment, and Development Conference

189. Addressing Stress and Burnout in Hematology/Oncology Physicians

195. A novel MYC –non ‐ IG fusion in refractory diffuse large B‐cell lymphoma

196. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

197. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

199. Two Step Anti-Thymocyte Globulin (ATG) Is Associated with No Severe Acute Graft Versus Host Disease and Favorable Immune Reconstitution Post Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

200. Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

Catalog

Books, media, physical & digital resources